$PZG
Paramount Gold Nevada Corp

2023 Q3 Form 10-K Financial Statement

#000095017023049730 Filed on September 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $90.00K $90.00K $180.0K
YoY Change 1405.02% 2150.0% -45.61%
Cost Of Revenue $160.0K $160.0K $630.0K
YoY Change -0.66% -1.85% -1.62%
Gross Profit -$70.00K -$70.00K -$450.0K
YoY Change -54.86% -55.98% 45.45%
Gross Profit Margin -77.78% -77.78% -250.0%
Selling, General & Admin $500.0K $560.0K $2.530M
YoY Change -21.23% -1.58% 13.49%
% of Gross Profit
Research & Development $1.260M $690.0K $2.600M
YoY Change 50.07% -4.46% -41.39%
% of Gross Profit
Depreciation & Amortization $342.00 $0.00 $1.934K
YoY Change -29.63% -100.0% -10.88%
% of Gross Profit
Operating Expenses $2.025M $1.360M $6.209M
YoY Change 15.89% 1.69% -9.37%
Operating Profit -$2.025M -$1.430M -$6.209M
YoY Change 15.89% -4.44% -13.29%
Interest Expense -$130.0K -$130.0K -$460.0K
YoY Change 31.63% 29.97% 15.32%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.070M -$1.570M -$6.488M
YoY Change 12.49% -1.66% -14.17%
Income Tax -$40.00K -$37.58K
% Of Pretax Income
Net Earnings -$2.074M -$1.530M -$6.451M
YoY Change 12.71% -18.36% -17.69%
Net Earnings / Revenue -2304.62% -1700.0% -3583.63%
Basic Earnings Per Share -$0.04 -$0.13
Diluted Earnings Per Share -$0.04 -$0.03 -$0.13
COMMON SHARES
Basic Shares Outstanding 58.88M 49.92M 48.70M
Diluted Shares Outstanding 56.30M 48.70M

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.010M $820.0K $820.0K
YoY Change -20.56% -66.99% -66.99%
Cash & Equivalents $1.014M $824.9K $820.0K
Short-Term Investments
Other Short-Term Assets $1.490M $1.470M $1.470M
YoY Change 68.73% 14.76% 14.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.502M $2.297M $2.300M
YoY Change 16.13% -38.99% -38.91%
LONG-TERM ASSETS
Property, Plant & Equipment $4.237K $4.579K $51.46M
YoY Change -29.7% -99.99% -0.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $550.0K $550.0K $550.0K
YoY Change 10.38% 10.38% 10.38%
Total Long-Term Assets $52.01M $52.01M $52.01M
YoY Change -0.46% -0.46% -0.45%
TOTAL ASSETS
Total Short-Term Assets $2.502M $2.297M $2.300M
Total Long-Term Assets $52.01M $52.01M $52.01M
Total Assets $54.51M $54.31M $54.31M
YoY Change 0.2% -3.05% -3.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.880M $940.0K $940.0K
YoY Change 281.78% 47.28% 47.28%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.620M $1.580M $1.580M
YoY Change
Long-Term Debt Due $4.170M $4.270M $4.270M
YoY Change -1.58%
Total Short-Term Liabilities $10.23M $9.350M $9.350M
YoY Change 111.0% 1133.08% 1133.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $1.960M $1.880M $1.880M
YoY Change -55.82% -56.83% -56.83%
Total Long-Term Liabilities $2.197M $2.116M $1.880M
YoY Change -53.4% -75.32% -78.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.23M $9.350M $9.350M
Total Long-Term Liabilities $2.197M $2.116M $1.880M
Total Liabilities $12.43M $11.47M $11.47M
YoY Change 29.96% 19.28% 19.32%
SHAREHOLDERS EQUITY
Retained Earnings -$76.40M -$74.32M
YoY Change 9.59% 9.5%
Common Stock $118.5M $117.2M
YoY Change 3.43% 2.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.08M $42.84M $42.84M
YoY Change
Total Liabilities & Shareholders Equity $54.51M $54.31M $54.31M
YoY Change 0.2% -3.05% -3.04%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$2.074M -$1.530M -$6.451M
YoY Change 12.71% -18.36% -17.69%
Depreciation, Depletion And Amortization $342.00 $0.00 $1.934K
YoY Change -29.63% -100.0% -10.88%
Cash From Operating Activities -$899.3K -$1.960M -$5.252M
YoY Change -25.84% 5.17% -21.62%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $80.00K
YoY Change -267.64%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$50.00K -$50.00K
YoY Change
Cash From Investing Activities $0.00 -$50.00K -$126.7K
YoY Change 165.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.220M
YoY Change -63.73%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.089M 2.250M 3.720M
YoY Change -2480.2% -39.22%
NET CHANGE
Cash From Operating Activities -899.3K -1.960M -5.252M
Cash From Investing Activities 0.000 -50.00K -126.7K
Cash From Financing Activities 1.089M 2.250M 3.720M
Net Change In Cash 189.2K 240.0K -1.659M
YoY Change -115.6% -112.26% 163.83%
FREE CASH FLOW
Cash From Operating Activities -$899.3K -$1.960M -$5.252M
Capital Expenditures $0.00 $80.00K
Free Cash Flow -$1.960M -$5.332M
YoY Change 5.17% -19.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001629210
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q2 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q2 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Income Tax Examination Year Under Examination
IncomeTaxExaminationYearUnderExamination
2019 2020 2021 2022 2023
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36908
CY2023 dei Entity Registrant Name
EntityRegistrantName
PARAMOUNT GOLD NEVADA CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0138393
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Anderson Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Winnemucca
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89445
CY2023 dei City Area Code
CityAreaCode
775
CY2023 dei Local Phone Number
LocalPhoneNumber
625-3600
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Trading Symbol
TradingSymbol
PZG
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
14746396
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58880646
CY2023 dei Auditor Name
AuditorName
Moss Adams LLP
CY2023 dei Auditor Firm
AuditorFirmId
659
CY2023 dei Auditor Firm
AuditorFirmId
659
CY2023 dei Auditor Location
AuditorLocation
Denver, Colorado
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
824920
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2484156
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1472286
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1280895
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2297206
CY2022Q2 us-gaap Assets Current
AssetsCurrent
3765051
CY2023Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51458261
CY2022Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51742873
CY2023Q2 pzg Reclamation Bond Noncurrent
ReclamationBondNoncurrent
546176
CY2022Q2 pzg Reclamation Bond Noncurrent
ReclamationBondNoncurrent
498276
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4579
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6513
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
52009016
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
52247662
CY2023Q2 us-gaap Assets
Assets
54306222
CY2022Q2 us-gaap Assets
Assets
56012713
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
937219
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
638256
CY2023Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
2560515
CY2022Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
120000
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
3614465
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
658363
CY2023Q2 pzg Notes Payable Related Parties
NotesPayableRelatedParties
1579397
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9349959
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
758256
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
3570430
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
651380
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
240043
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
277627
CY2023Q2 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
1876387
CY2022Q2 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
4355270
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2116430
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8854707
CY2023Q2 us-gaap Liabilities
Liabilities
11466389
CY2022Q2 us-gaap Liabilities
Liabilities
9612963
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54812248
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54812248
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46591081
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46591081
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
548124
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
465912
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
116613503
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
113805101
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74321794
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67871263
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
42839833
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
46399750
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54306222
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56012713
CY2023 us-gaap Exploration Expense
ExplorationExpense
2595709
CY2022 us-gaap Exploration Expense
ExplorationExpense
4436266
CY2023 pzg Land Holding Costs
LandHoldingCosts
632484
CY2022 pzg Land Holding Costs
LandHoldingCosts
640349
CY2023 us-gaap Professional Fees
ProfessionalFees
377822
CY2022 us-gaap Professional Fees
ProfessionalFees
130765
CY2023 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1238895
CY2022 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1196302
CY2023 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
143192
CY2022 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
113717
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
774817
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
790668
CY2023 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
446245
CY2022 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
183693
CY2023 us-gaap Operating Expenses
OperatingExpenses
6209164
CY2022 us-gaap Operating Expenses
OperatingExpenses
7491760
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-6209164
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-7491760
CY2023 us-gaap Other Income
OtherIncome
184059
CY2022 us-gaap Other Income
OtherIncome
330971
CY2023 pzg Interest And Service Charges
InterestAndServiceCharges
463010
CY2022 pzg Interest And Service Charges
InterestAndServiceCharges
398900
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6488115
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7559689
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-37584
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
277627
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6450531
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7837316
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48695858
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48695858
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42354842
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42354842
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
46399750
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
349992
CY2023 pzg Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
2219796
CY2023 pzg Stock Issued During Period Value Payment Of Interest Accrued
StockIssuedDuringPeriodValuePaymentOfInterestAccrued
320826
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6450531
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
42839833
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
47352730
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
440327
CY2022 pzg Stock Issued During Period Value Private Placement
StockIssuedDuringPeriodValuePrivatePlacement
6119954
CY2022 pzg Stock Issued During Period Value Payment Of Interest Accrued
StockIssuedDuringPeriodValuePaymentOfInterestAccrued
324055
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7837316
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
46399750
CY2023 us-gaap Profit Loss
ProfitLoss
-6450531
CY2022 us-gaap Profit Loss
ProfitLoss
-7837316
CY2023 us-gaap Depreciation
Depreciation
1934
CY2022 us-gaap Depreciation
Depreciation
2169
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349992
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
440327
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
51018
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
60308
CY2023 pzg Interest Expense Income
InterestExpenseIncome
240702
CY2022 pzg Interest Expense Income
InterestExpenseIncome
325283
CY2023 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
446245
CY2022 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
183693
CY2023 us-gaap Asset Retirement Obligation Cash Paid To Settle
AssetRetirementObligationCashPaidToSettle
120001
CY2022 us-gaap Asset Retirement Obligation Cash Paid To Settle
AssetRetirementObligationCashPaidToSettle
33236
CY2023 pzg Increase Decrease In Reclamation Bonds Accounts
IncreaseDecreaseInReclamationBondsAccounts
1200
CY2022 pzg Increase Decrease In Reclamation Bonds Accounts
IncreaseDecreaseInReclamationBondsAccounts
-35427
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-37584
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
277627
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
191391
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
153499
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
458484
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1922
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5252332
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6701139
CY2023 pzg Payments To Acquire Reclamation Bond
PaymentsToAcquireReclamationBond
46700
CY2023 pzg Payment To Acquire Mineral Properties
PaymentToAcquireMineralProperties
80000
CY2022 pzg Payment To Acquire Mineral Properties
PaymentToAcquireMineralProperties
45000
CY2022 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
2723
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-126700
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47723
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2219796
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6119954
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1500000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3719796
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6119954
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1659236
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-628908
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2484156
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3113064
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
824920
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2484156
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Significant estimates made by management in the accompanying consolidated financial statements include the adequacy of the Company’s reclamation and environmental obligation, share based compensation, valuation of deferred tax asset, and assessment of impairment of mineral properties.</span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash and cash equivalents. The Company maintains cash in accounts which may, at times, exceed federally insured limits. At June 30, 2023 and 2022, the Company had $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">2.23</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> million, respectively, of balances in excess of federally insured limits. </span><span style="font-size:10pt;font-family:'Times New Roman',serif;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Company deposits its cash with financial institutions which it believes have sufficient credit quality to minimize the risk of loss</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">.</span></p>
CY2023Q2 pzg Concentration Of Credit Risk Uninsured Cash Amount
ConcentrationOfCreditRiskUninsuredCashAmount
600000
CY2022Q2 pzg Concentration Of Credit Risk Uninsured Cash Amount
ConcentrationOfCreditRiskUninsuredCashAmount
2230000
CY2023 pzg Cash Uninsured Amount Description
CashUninsuredAmountDescription
The Company deposits its cash with financial institutions which it believes have sufficient credit quality to minimize the risk of loss
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
425500
CY2023 pzg Fair Value Of Shares Issued For Equity Compensation Plans
FairValueOfSharesIssuedForEquityCompensationPlans
142650
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
266000
CY2022 pzg Fair Value Of Shares Issued For Equity Compensation Plans
FairValueOfSharesIssuedForEquityCompensationPlans
170240
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
0
CY2022Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
0
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
425500
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
266000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349992
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
440327
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1033998
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
288332
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.53
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
88333
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0.73
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
657333
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.55
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.19
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
95002
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.41
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
153995
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0.82
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
458336
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.47
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8174
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22960
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M20D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
26552
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
152486
CY2022 pzg Restitution Payment
RestitutionPayment
4000
CY2023 us-gaap Other Income
OtherIncome
184059
CY2022 us-gaap Other Income
OtherIncome
330971
CY2023 pzg Exploration And Development Expenses
ExplorationAndDevelopmentExpenses
2595709
CY2023Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51458261
CY2022Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51742873
CY2023Q2 pzg Reclamation Bond Noncurrent
ReclamationBondNoncurrent
546176
CY2022Q2 pzg Reclamation Bond Noncurrent
ReclamationBondNoncurrent
498276
CY2023 us-gaap Financial Guarantee Insurance Contracts Claim Liability Weighted Average Risk Free Discount Rate
FinancialGuaranteeInsuranceContractsClaimLiabilityWeightedAverageRiskFreeDiscountRate
0.0993
CY2022 us-gaap Financial Guarantee Insurance Contracts Claim Liability Weighted Average Risk Free Discount Rate
FinancialGuaranteeInsuranceContractsClaimLiabilityWeightedAverageRiskFreeDiscountRate
0.0994
CY2023 pzg Weighted Average Inflation Rate
WeightedAverageInflationRate
0.0249
CY2022 pzg Weighted Average Inflation Rate
WeightedAverageInflationRate
0.0232
CY2023 pzg Land Holding Costs
LandHoldingCosts
632484
CY2023Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51458261
CY2022 pzg Exploration And Development Expenses
ExplorationAndDevelopmentExpenses
4436266
CY2022 pzg Land Holding Costs
LandHoldingCosts
640349
CY2022Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4475270
CY2021Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
1849644
CY2023 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
446245
CY2022 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
183693
CY2023 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
-364612
CY2022 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
2475169
CY2023 us-gaap Asset Retirement Obligation Liabilities Settled
AssetRetirementObligationLiabilitiesSettled
120001
CY2022 us-gaap Asset Retirement Obligation Liabilities Settled
AssetRetirementObligationLiabilitiesSettled
33236
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4436902
CY2022Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4475270
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4436902
CY2022Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4475270
CY2023Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
2560515
CY2022Q2 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
120000
CY2023Q2 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
1876387
CY2022Q2 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
4355270
CY2023 us-gaap Insurance Recoveries
InsuranceRecoveries
178084
CY2022 us-gaap Insurance Recoveries
InsuranceRecoveries
321113
CY2023 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
5975
CY2022 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
5858
CY2022Q2 us-gaap Mineral Properties Net
MineralPropertiesNet
51742873
CY2023Q2 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
30375155
CY2022Q2 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
23983360
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6488115
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7559689
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1362504
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1587535
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
309
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
164
CY2023 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-4249
CY2022 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-1094670
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1328860
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2959667
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-37584
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
277627
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-37584
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
277627

Files In Submission

Name View Source Status
pzg-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-049730-index-headers.html Edgar Link pending
0000950170-23-049730-index.html Edgar Link pending
0000950170-23-049730.txt Edgar Link pending
0000950170-23-049730-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img161943698_0.jpg Edgar Link pending
img161943698_1.jpg Edgar Link pending
img161943698_2.jpg Edgar Link pending
img161943698_3.jpg Edgar Link pending
img161943698_4.jpg Edgar Link pending
img161943698_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pzg-20230630.htm Edgar Link pending
pzg-20230630.xsd Edgar Link pending
pzg-ex21_1.htm Edgar Link pending
pzg-ex23_1.htm Edgar Link pending
pzg-ex23_2.htm Edgar Link pending
pzg-ex23_3.htm Edgar Link pending
pzg-ex23_4.htm Edgar Link pending
pzg-ex23_5.htm Edgar Link pending
pzg-ex23_6.htm Edgar Link pending
pzg-ex23_7.htm Edgar Link pending
pzg-ex31_1.htm Edgar Link pending
pzg-ex31_2.htm Edgar Link pending
pzg-ex32_1.htm Edgar Link pending
pzg-ex32_2.htm Edgar Link pending
pzg-ex4_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
pzg-20230630_def.xml Edgar Link unprocessable
pzg-20230630_lab.xml Edgar Link unprocessable
pzg-20230630_pre.xml Edgar Link unprocessable
pzg-20230630_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending